CUPR צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Cuprina Holdings Ltd

The current quarterly EPS growth rate reflects market expectations, while -224.50 captures the magnitude of this parameter. Cuprina Holdings (CUPR) is implementing advanced biotechnologies to combat diabetic foot. Growth is driven by the scaling of innovative dressings and expansion into hospital markets. The development model relies on contract manufacturing, which minimizes capital expenditures while maintaining control over patents.
פילוחי נתונים אנליטיים מרוכזים עבור cuprina.com.sg (CUPR)

To identify fundamentally resilient assets, investors evaluate the dynamics of net earnings per share, which measures the rate of change in return on equity per quarter. The current value of -224.50 reflects the monetization efficiency of medical materials at Cuprina Holdings (CUPR), allowing the quarterly growth in earnings per share to determine the extent to which stable working capital is converted into real growth in shareholder value.